To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.

Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Diagnostics manufacturer Quidel reported after the close of the market on Thursday that its fourth quarter revenues fell more than 21 percent year over year due primarily to shift in product mix and decreased COVID-19 product sales.

On February 17, 2022, Roche Diagnostics China announced in Shanghai that it had reached a strategic partnership with Sanomede Medical Technology Co., Ltd. (hereinafter referred to as "Sanomede") to jointly launch a new RS600 Lab Automation System (LAS) for Chinese market.

Recently, Hong Kong has been hit by the epidemic continuously. On February 16, Kang Keren, senior vice president of Wondfo Biotech, said that in response to the epidemic in Hong Kong, Wondfo's "Anti-epidemic pioneer" is preparing to go to the front line and guarantee supply.

The European Union’s In Vitro Diagnostics Regulation (IVDR) is set to take effect May 26, 2022, but a recent effort to amend the transitional provisions of the new regulation may bring some relief.

Thermo Fisher Scientific's solution for cell and gene therapies involves a combination of cold chain logistics, serialization compliance, and distribution

Researchers at the University of Toronto have identified hundreds of new proteins that could play a role in cystic fibrosis, and which may shed light on why some patients respond better than others to current therapies.

Pacific Biosciences reported after the close of the market on Tuesday that its fourth quarter 2021 revenues grew 33 percent year over year, while its full-year revenues jumped 65 percent.

On 12 February, the second meeting between the Mainland and Hong Kong on the COVID-19 outbreak as held in Shenzhen as the COVID-19 continued to spread in Hong Kong and confirmed cases continued to soar.

At the end of the reporting period, the total assets of Wantai Biopharmwere CNY 7.047 billion, an increase of 101.13% over the beginning of the period.

Olink reported before the opening of the market Monday that its Q4 revenues rose 61 percent.